Literature DB >> 34133161

Phytocompounds Targeting Metabolic Reprogramming in Cancer: An Assessment of Role, Mechanisms, Pathways, and Therapeutic Relevance.

Asifa Khan1,2, Shumaila Siddiqui1, Syed Akhtar Husain2, Sybille Mazurek3, Mohammad Askandar Iqbal1.   

Abstract

The metabolism of cancer is remarkably different from that of normal cells and confers a variety of benefits, including the promotion of other cancer hallmarks. As the rewired metabolism is a near-universal property of cancer cells, efforts are underway to exploit metabolic vulnerabilities for therapeutic benefits. In the continued search for safer and effective ways of cancer treatment, structurally diverse plant-based compounds have gained substantial attention. Here, we present an extensive assessment of the role of phytocompounds in modulating cancer metabolism and attempt to make a case for the use of plant-based compounds in targeting metabolic vulnerabilities of cancer. We discuss the pharmacological interactions of phytocompounds with major metabolic pathways and evaluate the role of phytocompounds in the regulation of growth signaling and transcriptional programs involved in the metabolic transformation of cancer. Lastly, we examine the potential of these compounds in the clinical management of cancer along with limitations and challenges.

Entities:  

Keywords:  Warburg effect; cancer metabolism; cancer therapy; growth signaling; metabolic reprogramming; phytocompounds

Year:  2021        PMID: 34133161     DOI: 10.1021/acs.jafc.1c01173

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  2 in total

Review 1.  Boosting the Discovery of Small Molecule Inhibitors of Glucose-6-Phosphate Dehydrogenase for the Treatment of Cancer, Infectious Diseases, and Inflammation.

Authors:  Ana Koperniku; Adriana A Garcia; Daria Mochly-Rosen
Journal:  J Med Chem       Date:  2022-03-03       Impact factor: 8.039

2.  Smilax china root extract as a novel Glucose- 6-phosphate dehydrogenase inhibitor for the treatment of hepatocellular carcinoma.

Authors:  Lubna Kanwal; Shaukat Ali; Azhar Rasul; Hafiz Muhammad Tahir
Journal:  Saudi J Biol Sci       Date:  2022-07-30       Impact factor: 4.052

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.